Kromek Group PLC (LON:KMK) said it has started development of a new system to improve pathological medical imaging techniques used during cancer surgery to distinguish between healthy and non-healthy tissue.
The detection technology specialist said the three-year project, which has received a grant from Innovate UK and is being conducted in partnership with medical imaging firm Adaptix and the University of Manchester, is aiming to develop a prototype of a new type of pathology cabinet, based on Kromek’s CZT detectors and Adaptix’s Flat Panel X-Ray Source technology.
The prototype will produce high-resolution 3D images that provide more accurate differentiation of the boundaries between cancerous and healthy tissue, enabling surgeons to remove the minimum amount of healthy tissue when extracting cancer tumours and reduce the risk of more than one operation being needed and of cancer spreading from diseased tissue left after the initial surgery.
It is not the first instance of Kromek’s CZT being used in medical devices, with the technology currently used for early detection of diseases such as breast cancer, cardiac conditions and osteoporosis.
“This is an exciting project for Kromek as it takes our CZT-based detectors into a new application area. Our technology is already being used by leading OEMs to enable the early diagnosis of cancer. With this system, we will contribute to improving the outcome of surgeries through greater image quality”, Kromek chief executive Arnab Basu said in a statement.
“It will reduce the risk of diseased tissue remaining and further surgeries being required while minimising the removal of healthy tissue, which will be of great benefit to both healthcare providers and patients. We look forward to working alongside our partners, Adaptix and the University of Manchester, to complete the development of this new system and take it to the next stage”, he added.
Shares in Kromek rose 4.1% to 13.7p in early trading on Wednesday.